Revelation Biosciences, Inc. (NASDAQ:REVB – Free Report) – Stock analysts at Zacks Research issued their Q1 2027 EPS estimates for Revelation Biosciences in a research report issued on Friday, November 6th. Zacks Research analyst B. Sorensen forecasts that the company will post earnings per share of ($4.71) for the quarter. The consensus estimate for Revelation Biosciences’ current full-year earnings is ($35.08) per share. Zacks Research also issued estimates for Revelation Biosciences’ Q2 2027 earnings at ($4.10) EPS, Q3 2027 earnings at ($4.05) EPS and Q4 2027 earnings at ($4.92) EPS.
Separately, Weiss Ratings upgraded shares of Revelation Biosciences from a “sell (e)” rating to a “sell (e+)” rating in a research note on Tuesday. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, Revelation Biosciences presently has a consensus rating of “Sell”.
View Our Latest Stock Analysis on Revelation Biosciences
Revelation Biosciences Price Performance
Revelation Biosciences stock opened at $4.15 on Thursday. The company’s 50-day moving average is $5.27 and its 200-day moving average is $7.52. The firm has a market capitalization of $2.84 million, a PE ratio of -0.10 and a beta of -0.13. Revelation Biosciences has a fifty-two week low of $3.08 and a fifty-two week high of $40.60.
Revelation Biosciences (NASDAQ:REVB – Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($5.92) EPS for the quarter, beating analysts’ consensus estimates of ($6.16) by $0.24.
About Revelation Biosciences
Revelation Biosciences, Inc. is a clinical-stage biotechnology company focused on developing therapies that stimulate the body’s innate immune system. The company’s research is centered on immunologic treatments intended to help prevent or manage infectious and other acute diseases. Its lead development programs are based on Gemini, a proprietary toll-like receptor 4 agonist designed to activate innate immune responses. Revelation has investigated intranasal formulations, including REVTx-99, for potential use against respiratory viral infections, as well as other candidates aimed at addressing serious medical conditions such as sepsis.
Recommended Stories
- Five stocks we like better than Revelation Biosciences
- Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-Off
- Palantir’s Real Washington Risk Isn’t the Budget—It’s Oversight
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
Receive News & Ratings for Revelation Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revelation Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
